Skip to main content

Table 1

From: Interstitial lung disease in patients with scleroderma - Treatment with rituximab

  Pat.1. Pre-RTX Pat.1. Post-RTX Pat.2. Pre-RTX Pat.2. Post-RTX Pat. 3. Pre-RTX Pat.3. Post-RTX
Vital Cap (L) 1.94 (65.2%) 2.02 (68.5%) 1.08 (44.8%) 1.15 (48.3%) 1.43 (53.4%) 1.51 (56.7%)
FEV 1 1.75 (68.6%) 1.81 (71.6%) 1.08 (53.1%) 1.09 (54.5%) 1.12 (49.2%) 1.18 (52.2%)
FEV1/VC 90.35 89.69 99.91 94.86 78.38 78.15
TLCOc/VA (mol/min/Kpa) 1.20 (68%) 1.03 (59.2%) 0.93 (54.8%) 1.02 (60.6%) 1.20 (68.0%) 1.29 (73,8%)
PCO2 (mmHg) 44.1 42.8 32.6 40.2 33 35.1
PO2 (mmHg) 83 86 84 92 64 75
Sat O2 (%) 94.2 96.6 96.7 97.4 94.4 96.3